Prosthetic Valve Endocarditis caused by HACEK Organisms: a Case Report and Systematic Review of the Literature

Ha Na Choi, Ki-Ho Park, Soyoung Park, Jae-Min Kim, Hyun Joon Kang, Jae Hun Park, and Mi Suk Lee
Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University School of Medicine, Seoul, Korea

HACEK is a rare cause of prosthetic valve endocarditis (PVE). We describe 42-year-old male patient who presented with *Aggregatibacter aphrophilus* PVE and cerebral infarct. *A. aphrophilus* was isolated from his blood cultures as the sole pathogen, which was confirmed by subsequent 16S rRNA sequencing. He was treated with valve replacement surgery and an 8 week course of pathogen-directed antibiotic therapy and followed for 20 months without recurrence.

**Key Words:** HACEK; *Aggregatibacter aphrophilus*; Endocarditis; Heart valve prosthesis.

**Introduction**

HACEK is an acronym comprising the first letters of the generic names of the following group of bacteria: *Haemophilus parainfluenzae*, *Aggregatibacter actinomycetemcomitans*, *Aggregatibacter aphrophilus*, *Aggregatibacter paraphrophilus*, *Cardiobacterium* spp., *Eikenella corrodens* and *Kingella* spp.. These organisms are fastidious Gram-negative bacteria found in the human upper respiratory and genitourinary tracts [1, 2]. The microorganisms are generally considered to be of low virulence and to infect structurally damaged or prosthetic cardiac valves. Clinically, these cases are characterized by a subacute or chronic course and often present with embolic lesions from large vegetations and congestive cardiac failure [3]. A favorable prognosis with medical treatment [2, 4, 5] and a high incidence of large systemic emboli and heart failure have been reported [6-8]. This favorable prognosis is likely based on overestimation of positive outcomes due to considerable bias towards under-reporting unfavorable cases [9].

HACEK accounts for approximately 5–10% of native valve community-acquired endocarditis in patients who are not intravenous drug users [10] but is a rare cause (1.4%) of prosthetic valve endocarditis (PVE) [11]. Therefore, there are limited data on the clinical characteristics and outcomes of PVE caused by HACEK organisms, and the optimum treatment in patients with PVE due to HACEK is controversial. In this paper, we describe a patient who presented with HACEK PVE of the mechanical mitral valve from whom *Aggregatibacter*
aphrophilus was isolated as the sole pathogen. We also review the English-language literature on A. aphrophilus PVE.

Case Report

A 42-year-old male presented to our hospital with fever and jaundice. He had undergone mitral valve replacement 25 years prior because of rheumatic heart disease. He had no recent history of dental manipulation or any intervention. An initial physical examination showed fever of up to 38.2°C and general weakness. All of his body's skin and sclera were yellow. Abdominal examination did not reveal any abnormalities. There was no peripheral sign of endocarditis. His white blood cell count was $22.22 \times 10^3$/mm$^3$, hemoglobin was 11.6 g/dL, and platelet count was $133 \times 10^3$/mm$^3$. The following values were also increased from normal levels: serum alanine transaminase, 47 U/L (normal range, 10–40 U/L); serum total bilirubin, 17.83 mg/dL (normal range, 0.2–1.1 mg/dL); serum direct bilirubin, 14.31 mg/dL (normal range, 0.2–0.5 mg/dL); serum alkaline phosphatase, 209 U/L (normal range, 39–108 U/L); creatinine, 1.3 mg/dL (normal range, 0.6–1.2 mg/dL); and C-reactive protein, 16.47 mg/dL (normal range, < 0.3 mg/dL). Microscopic hematuria was evident.

Abdominal computed tomography (CT) revealed a partial splenic infarction within the distal splenic artery. There was no evidence of cholangitis. A chest radiograph showed pulmonary edema. An electrocardiogram revealed atrial fibrillation. A transthoracic echocardiogram (TTE) was unremarkable but showed moderate pulmonary hypertension. A transesophageal echocardiogram (TEE) showed thrombus and vegetation in the mechanical mitral valve of a flail nature.

After confirmation of the presence of vegetation by TEE, treatment was started with nafcillin (2 g every 4 h) and vancomycin (1 g every 12 h), based on the assumption that Gram-negative bacteria are a rare cause of PVE and methicillin-resistant and susceptible staphylococci are most common cause of PVE. On hospital day 7, the patient showed dysarthria, left-sided weakness and drowsy mentality. Brain diffusion MRI showed acute cerebral infarction (Fig. 1). Non-sustained ventricular tachycardia appeared, and a repeat TTE showed progression of the thrombus on the mitral valve (Fig. 2). The blood culture drawn on the day of admission was reported on hospital day 9 to be positive for A. aphrophilus. This organism was confirmed by subsequent 16S rRNA sequencing. Based on the identified organism and susceptibility, antibiotic treatment was changed to intravenous ceftriaxone (2 g every 24 h) and ciprofloxacin (800 mg every 12 h) and continued for 8 weeks. On hospital day 12, the patient underwent thoracic surgery. The cultures for ordinary bacteria, fungi, and mycobacteria from surgical samples were all negative. The infected mitral valve prosthesis and left upper pulmonary vein thrombus were removed during the operation. The patient was clinically healthy and remained afebrile, but he had only partly recovered from his neurological handicap and exhibited gait disturbance at 20 months after discharge.

Discussion

Our review of the English-language literature revealed 7 cases of A. aphrophilus HACEK PVE (Table 1) [11-14]. We found that the outcome of HACEK PVE was favorable, as indicated
Table 1. Clinical features of eight patients with infections due to *Aphrophilus aphrophilus*

| Case No. [Reference] | Age/Sex | Prosthesis | Predisposing factor | Symptom Onset (day) | Complication | Diagnosis | Surgical management | Primary antibiotic therapy (total duration of therapy) | Outcome |
|----------------------|---------|------------|---------------------|---------------------|--------------|-----------|---------------------|------------------------------------------------------|----------|
| 1 [11]               | 48/F    | MVR        | None                | 1                   | Cerebral infarct | Possible IE | None                | Cefalothin (42 days)                                  | Cured    |
| 2 [12]               | 41/F    | MVR        | ND                  | ND                  | None          | Possible IE | Valve replacement   | Penicillin (40 days)                                  | Cured    |
| 3 [12]               | 70/M    | AVR        | ND                  | ND                  | None          | Possible IE | Valve replacement   | Penicillin plus streptomycin (6 weeks)               | Expired  |
| 4 [13]               | 69/M    | AVR        | ND                  | ND                  | None          | Possible IE | Valve replacement   | Penicillin (12 weeks)                                 | Cured    |
| 5 [13]               | 48/F    | MVR        | ND                  | ND                  | None          | Possible IE | None                | Penicillin plus streptomycin (7 weeks)               | Cured    |
| 6 [14]               | 56/F    | AVR        | Previous IE         | 60                  | None          | Possible IE | None                | Amoxicillin and ofloxacin (34 days)                  | Cured    |
| 7 [14]               | 55/M    | AVR        | Previous IE         | 330                 | None          | Possible IE | None                | Cefixime and ofloxacin (56 days)                     | Cured    |
| Present case         | 42/M    | MVR        | None                | 1                   | Cerebral infarct | Definite IE | None                | Ceftriazone plus ciprofloxacin (8 weeks)            | Cured    |

*According to modified Duke criteria.
F, female; MVR, mitral valve replacement; M, male; AVR, aortic valve replacement; IE, infective endocarditis; ND, not described.

Conflicts of Interest

No conflicts of interest.

References

1. Brouqui P, Raoult D. Endocarditis due to rare and fastidious bacteria. Clin Microbiol Rev 2001;14:177-207.
2. Das M, Bailey AD, Cockerill FR, Steckelberg JM, Wilson WR. Infective endocarditis caused by HACEK microorganism. Am J Med 1999;106:482-85.
3. Warinner GP, Botene B. Cardiobacteria hominis: recent advances. Ann Rev Med. 1997;48:45-53.
view of microbiologic and clinical features. Rev Infect Dis 1983;5:680-91.
4. Meyer DJ, Gerding DN. Favorable prognosis of patients with prosthetic valve endocarditis caused by gram-negative bacilli of the HACEK group. Am J Med 1988;85:104-7.
5. el Khizzi N, Kasab SA, Osoba AO. HACEK group endocarditis at the Riyadh Armed Forces Hospital. J Infect 1997;34:69-74.
6. Tornos P, Sanz E, Pernyander-Miralda G, Almirante B, Planes AM, Soler-Soler J. Late prosthetic valve endocarditis. Immediate and long-term prognosis. Chest 1992;101:37-41.
7. Ellner JJ, Rosenthal MS, Lerner PI, McHenry MC. Infective endocarditis caused by slow-growing, fastidious, Gram-negative bacteria. Medicine (Baltimore) 1979;58:145-58.
8. Hall R, de Antueno C, Webber A; Canadian Research Ethics Board. Publication bias in the medical literature: a review by a Canadian Research Ethics Board. Can J Anaesth 2007;54:380-8.
9. Geraci JE, Wilson WR. Symposium on infective endocarditis. III. Endocarditis due to gram-negative bacteria. Report of 56 cases. Mayo Clin Proc 1982;57:145-8.
10. Wang A, Athan E, Pappas PA, Fowler VG Jr, Olaizon L, Paré C, Almirante B, Muñoz P, Rizzi M, Naber C, Logar M, Tattevin P, Larussi DL, Selton-Suty C, Jones SB, Casabé J, Morris A, Corey GR, Cabell CH; International Collaboration on Endocarditis-Prospective Cohort Study Investigators. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA 2007;297:1354-61.
11. Goldsweig HG, Matsen JM, Castaneda AR. Hemophilus aphrophilus endocarditis in a patient with a mitral valve prosthesis. Case report and review of the literature. J Thorac Cardiovasc Surg 1972;63:408-11.
12. Geraci JE, Wilkowske CJ, Wilson WR, Washington JA 2nd. Haemophilus endocarditis. Report of 14 patients. Mayo Clin Proc 1977;52:209-15.
13. Bieger RC, Brewer NS, Washington JA 2nd. Haemophilus aphrophilus: a microbiologic and clinical review and report of 42 cases. Medicine (Baltimore) 1978;57:345-55.
14. Darras-Joly C, Lortholary O, Mainardi JL, Etienne J, Guillevin L, Acar J. Haemophilus endocarditis: report of 42 cases in adults and review. Haemophilus Endocarditis Study Group. Clin Infect Dis 1997;24:1087-94.
15. Dickerman SA, Abrutyn E, Barsic B, Bouza E, Cecchi E, Moreno A, Doco-Lecompte T, Eisen DP, Fortes CQ, Fowler VG Jr, Lerakis S, Miro JM, Pappas P, Peterson GE, Rubinstein E, Sexton DJ, Suter E, Tornos P, Verhagen DW, Cabell CH; ICE Investigators. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J 2007;154:1086-94.
16. Chambers ST, Murdoch D, Morris A, Holland D, Pappas P, Almela M, Fernández-Hidalgo N, Almirante B, Bouza E, Forno D, del Rio A, Hannan MM, Harkness J, Kanafani ZA, Lalani T, Lang S, Raymond N, Read K, Vinogradova T, Woods CW, Wray D, Corey GR, Chu VH; International Collaboration on Endocarditis Prospective Cohort Study Investigators. HACEK infective endocarditis: characteristics and outcomes from a large, multi-national cohort. PLoS One 2013;8:e63181.